Table 3B.

Effect of immunoglobulins from 38 PBC patients on proliferation of mAChR3-expressing cholangiocytes before therapy and in the course without or with therapy.

PBC patients		Effect on proliferation
		None	Stimulatory	Inhibitory
		Number (%)
Without therapy (n = 4)	Time point of diagnosis	4 (100)	0	0
	After 9–177 months (median 103 months)	4 (100)	0	0
UDCA-therapy (n = 18)	Before therapy	17 (94)	0	1 (1)
	Under therapy (12–206 months, median 121 months)	18 (100)	0	0
Immunosuppressive therapy (n = 16)	Before therapy	16 (100)	0	0
	Under therapy (11–213 months, median 108 months)	15 (94)	0	1 (1)

Parenthesis reflects % patients' sera showing none, stimulatory, or inhibitory anti-mAChR3 reactivity. There were no significant differences between any of the groups.